Treatment of parkinsonism by amantadine and levodopa.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010549:Personal Satisfaction; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D013997:Time Factors
D010648:Phenylacetates; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D000547:Amantadine